OncoSec Announces Preliminary Data from KEYNOTE-695 Study Accepted for Late-Breaking Presentation at SITC Annual Meeting

SAN DIEGO and PENNINGTON, N.J., Nov. 2, 2018 /PRNewswire/ -- OncoSec Medical Incorporated (OncoSec) (NASDAQ:ONCS), a company developing intratumoral cancer immunotherapies, today announced that preliminary clinical and immunological data from its ongoing KEYNOTE-695 study, a global, multicenter, registration-directed Phase 2b trial of TAVO in combination with KEYTRUDA® for the treatment of metastatic melanoma, were accepted for a late-breaking Poster Presentation at the upcoming Society for Immunotherapy of Cancer (SITC) Annual Meeting to be held at the Walter E. Washington Convention Center in Washington, D.C. on November 7-11, 2018.

The details of the Poster Presentation are as follows:

Presentation Title: Initial report of intratumoral tavokinogene telseplasmid with pembrolizumab in advanced melanoma: an approach designed to convert PD-1 antibody progressors into responders.
Author: Atkinson, et. al.
Poster Number: P717
Presentation date: Friday, November 9 and Saturday, November 10, 2018

The late-breaking abstract titles can be found on the conference website here.

KEYTRUDA® is a registered trademark of Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA.

About OncoSec Medical Incorporated

OncoSec is a clinical-stage biotechnology company focused on developing cytokine-based intratumoral immunotherapies to stimulate the body's immune system to target and attack cancer.  OncoSec's lead immunotherapy platform – TAVO (tavokinogene telseplasmid) – enables the intratumoral delivery of DNA-based interleukin-12 (IL-12), a naturally occurring protein with immune-stimulating functions. The technology, which employs electroporation, is designed to produce a controlled, localized expression of IL-12 in the tumor microenvironment, enabling the immune system to target and attack tumors throughout the body. OncoSec has built a deep and diverse clinical pipeline utilizing TAVO as a potential treatment for multiple cancer indications either as a monotherapy or in combination with leading checkpoint inhibitors; with the latter potentially enabling OncoSec to address a great unmet medical need in oncology: anti-PD-1 non-responders.  Results from recently completed clinical studies of TAVO have demonstrated a local immune response, and subsequently, a systemic effect as either a monotherapy or combination treatment approach.  In addition to TAVO, OncoSec is identifying and developing new DNA-encoded therapeutic candidates and tumor indications for use with its ImmunoPulse® platform. For more information, please visit www.oncosec.com.

CONTACT
Investor Relations:
Stern Investor Relations
Will O'Connor
Phone: (212) 362-1200
will@sternir.com

Media Relations:
David Schemelia / Jason Rando
Tiberend Strategic Advisors, Inc. 
Phone: 212-827-0020
dschemelia@tiberend.com 
jrando@tiberend.com

OncoSec Medical Incorporated logo (PRNewsfoto/OncoSec Medical Incorporated)

 

Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/oncosec-announces-preliminary-data-from-keynote-695-study-accepted-for-late-breaking-presentation-at-sitc-annual-meeting-300743017.html

SOURCE OncoSec Medical Incorporated